With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep

 
• By Alaric DeArment
  
Open Book Of prostate multiple myeloma, Conceptual Image - Image
With two BCMA-targeting myeloma therapies available, the question now is how to position them in treatment • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Market Snapshot

More from Scrip